Initiation of insulin therapy in patients with type 2 diabetes: An observational study

1. M. J. Davies, D. A. D’Alessio, J. Fradkin, W. N. Kernan, C. Mathieu, G. Mingrone, P. Rossing, A. Tsapas, D. J. Wexler and J. B. Buse, Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care 41 (2018) 2669–2701; https://doi.org/10.2337/dci18-003310.2337/dci18-0033624520830291106 Search in Google Scholar

2. Slovenian Endocrinology Association, Slovenian Guidelines on Type 2 Diabetes Management 2016 [in Slovene]; https://endodiab.si/priporocila/smernice-za-vodenje-sladkorne-bolezni/; last access date November 30, 2020. Search in Google Scholar

3. P. Home, M. Riddle, W. T. Cefalu, C. J. Bailey, R. G. Bretzel, S. Del Prato, D. Leroith, G. Schernthaner, L. van Gaal and I. Raz, Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care 37 (2014) 1499–1508; https://doi.org/10.2337/dc13-274310.2337/dc13-2743513188424855154 Search in Google Scholar

4. M. D. Campbell, D. Babic, U. Bolcina, L. Smirčić-Duvnjak, T. Tankova, A. Mitrakou, P. Kempler and A. Janez, High level of clinical inertia in insulin initiation in type 2 diabetes across Central and South-Eastern Europe: insights from SITIP study, Acta Diabetol. 56 (2019) 1045–1049; https://doi.org/10.1007/s00592-019-01346-110.1007/s00592-019-01346-1667575330993528 Search in Google Scholar

5. G. Goodall, E. M. Sarpong, C. Hayes and W. J. Valentine, The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study, BMC Endocr. Disord. 9 (2009) Article ID 19 (9 pages); https://doi.org/10.1186/1472-6823-9-1910.1186/1472-6823-9-19276191319804622 Search in Google Scholar

6. T. Albreht, R. Pribaković Brinovec, D. Jošar, M. Poldrugovac, T. Kostnapfel, M. Zaletel, D. Panteli and A. Maresso, Slovenia: Health system review, Health Syst. Trans. 18 (2016) (207 pages); https://www.euro.who.int/_data/assets/pdf_file/0018/312147/HiT-Slovenia_rev3.pdf; last access date February 15, 2021. Search in Google Scholar

7. E. Chiefari, B. Arcidiacono, D. Foti and A. Brunetti, Gestational diabetes mellitus: an updated overview, J. Endocrinol. Invest. 40 (2017) 899–909; https://doi.org/10.1007/s40618-016-0607-510.1007/s40618-016-0607-528283913 Search in Google Scholar

8. O. Montvida, J. Shaw, J. J. Atherton, F. Stringer and S. K. Paul, Long-term trends in antidiabetes drug usage in the U.S.: Real-world evidence in patients newly diagnosed with type 2 diabetes, Diabetes Care 41 (2018) 69–78; https://doi.org/10.2337/dc17-141410.2337/dc17-141429109299 Search in Google Scholar

9. S. Wilkinson, I. Douglas, H. Stirnadel-Farrant, D. Fogarty, A. Pokrajac, L. Smeeth and L. Tomlinson, Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017, BMJ Open 8 (2018) e022768; https://doi.org/10.1136/bmjopen-2018-02276810.1136/bmjopen-2018-022768606740030056393 Search in Google Scholar

10. M. Sharma, I. Nazareth and I. Petersen, Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study, BMJ Open 6 (2016) e010210; https://doi.org/10.1136/bmjopen-2015-01021010.1136/bmjopen-2015-010210473517626769791 Search in Google Scholar

11. A. Ringborg, P. Lindgren, D. D. Yin, M. Martinell and J. Stalhammar, Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes, Diabetes Metab. 36 (2010) 198–203; https://doi.org/10.1016/j.diabet.2009.11.00610.1016/j.diabet.2009.11.00620347376 Search in Google Scholar

12. F. Persson, J. Bodegard, J. T. Lahtela, T. Nystrom, M. E. Jorgensen, M. L. Jensen, H. L. Gulseth, M. Thuresson, F. Hoti, D. Nathanson, A. Norhammar, K. I. Birkeland, J. G. Eriksson and J. W. Eriksson, Different patterns of second-line treatment in type 2 diabetes after metformin mono-therapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study, Endocrinol. Diabetes Metab. 1 (2018) e00036; https://doi.org/10.1002/edm2.3610.1002/edm2.36635481730815564 Search in Google Scholar

13. K. Kostev and W. Rathmann, Changes in time to insulin initiation in type 2 diabetes patients: a retrospective database analysis in Germany and UK (2005-2010), Prim. Care Diabetes 7 (2013) 229–233; https://doi.org/10.1016/j.pcd.2013.03.00310.1016/j.pcd.2013.03.00323608219 Search in Google Scholar

14. J. M. van den Heuvel, N. Farzan, M. van Hoek, A.-H. Maitland-van der Zee and F. Ahmadizar, Mining treatment patterns of glucose-lowering medications for type 2 diabetes in the Netherlands, BMJ Open Diabetes Res. Care 8 (2020) e000767; https://doi.org/10.1136/bmjdrc-2019-00076710.1136/bmjdrc-2019-000767695478231958296 Search in Google Scholar

15. T. Wilke, N. Picker, S. Mueller, S. Geier, J. Foersch, J. Aberle, S. Martin, M. Riedl and M. Gabler, Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage, Diabetes Metab. Syndr. Obes. 12 (2019) 1225–1237; https://doi.org/10.2147/DMSO.S21428810.2147/DMSO.S214288666432031440070 Search in Google Scholar

16. Y. Xu, S. J. Pilla, G. C. Alexander and I. B. Murimi, Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study, PLoS One 14 (2019) e0211820; https://doi.org/10.1371/journal.pone.021182010.1371/journal.pone.0211820637395330759121 Search in Google Scholar

17. K. Khunti, T. Damci, L. Meneghini, C. Y. Pan and J.-F. Yale, Study of once daily levemir (SOLVE^TM): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice, Diabetes Obes. Metab. 14 (2012) 654–661; https://doi.org/10.1111/j.1463-1326.2012.01602.x10.1111/j.1463-1326.2012.01602.x22443213 Search in Google Scholar

18. D. C. Beachler, G. Fernandes, G. Deshpande, J. Jemison, L. G. Lyons, S. Lanes, J. Liu and A. Mc-Neill, Patient and prescriber characteristics among patients with type 2 diabetes mellitus continuing or discontinuing sulfonylureas following insulin initiation: data from a large commercial database, Curr. Med. Res. Opin. 34 (2018) 1061–1069; https://doi.org/10.1080/03007995.2017.141634810.1080/03007995.2017.141634829264933 Search in Google Scholar

19. K. Khunti, M. B. Gomes, S. Pocock, M. V. Shestakova, S. Pintat, P. Fenici, N. Hammar and J. Medina, Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review, Diabetes Obes. Metab. 20 (2018) 427–437; https://doi.org/10.1111/dom.1308810.1111/dom.13088581323228834075 Search in Google Scholar